Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
5 min read
Anagenesis Biotechnologies SAS Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Anagenesis Biotechnologies SAS, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Andes Biotechnologies SA Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Andes Biotechnologies SA, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
AngioLab, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of AngioLab, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Anhui Anke Biotechnology (Group) Co., Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Anhui Anke Biotechnology (Group) Co., Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Anixa Biosciences, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Anixa Biosciences, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Amarna Therapeutics BV Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Amarna Therapeutics BV, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Alzamend Neuro, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Alzamend Neuro, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Amarantus Bioscience Holdings, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Amarantus Bioscience Holdings, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Alzinova AB Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Alzinova AB, covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
5 min read
Amrita Therapeutics Ltd. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Amrita Therapeutics Ltd., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
AlloVir, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of AlloVir, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.
Latest Hotspot
6 min read
Altay Therapeutics, Inc. Company BD Opportunity Scan Report 2026: Pipeline, Deals and Partnering Shortlist
24 July 2026
A 2026 partnering scan of Altay Therapeutics, Inc., covering pipeline ownership and stage, evidence requirements, IP risk, deal precedent, financial signals and a prioritized outreach shortlist.